Literature DB >> 9923802

Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease.

F F di Mola1, H Friess, A Scheuren, P Di Sebastiano, H Graber, B Egger, A Zimmermann, M Korc, M W Büchler.   

Abstract

OBJECTIVE: To evaluate mechanisms that contribute to tissue repair and tissue remodeling in Crohn's disease (CD). SUMMARY BACKGROUND DATA: Transforming growth factor-betas (TGF-betas) are involved in different chronic inflammatory disorders. They function by binding to two receptors, type I (TbetaR-I) subtype ALK5 and type II (TbetaR-II), which are concomitantly required for signal transduction.
METHODS: Tissues were obtained from 18 patients with CD (10 female patients, 8 male patients, median age 38.7 years [range 16 to 58 years]) undergoing surgery because of CD-related complications. Tissue samples of 18 healthy organ donors (10 female subjects, 8 male subjects, median age 50.3 years [range 15 to 65 years]) served as controls. The expression and localization of TGF-beta1, TGF-beta2, TGF-beta3, TbetaR-IALK5, TbetaR-II, and TbetaR-III were studied by Northern blot analysis, in situ hybridization, and immunohistochemistry.
RESULTS: On Northern blot analysis, 94% of the CD samples exhibited enhanced TGF-beta1, TGF-beta3, and TbetaR-II mRNA expression compared with controls. TGF-beta2 was increased in 72%, TbetaR-IALK5 in 72%, and TbetaR-III in 82% of the patients with CD. On in situ hybridization and immunohistochemical analysis, TGF-beta1, TbetaR-IALK5, and TbetaR-II were seen to be colocalized in the lamina propria cells and in the lymphocytes closest to the luminal surface, but also in the remaining epithelial cells, and in fibroblasts of CD tissue samples.
CONCLUSIONS: The concomitant overexpression of TGF-betas and their signaling receptors in CD points to a potential role of these regulatory molecules in the pathophysiology of CD. Activation of TGF-beta-mediated pathways might promote the repair of mucosal injury by enhancing the process of reepithelization, but might also contribute to extracellular matrix generation and subsequently to intramural fibrosis and intestinal obstruction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9923802      PMCID: PMC1191610          DOI: 10.1097/00000658-199901000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

Review 1.  The transforming growth factor-beta family.

Authors:  J Massagué
Journal:  Annu Rev Cell Biol       Date:  1990

2.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.

Authors:  A B Roberts; M B Sporn; R K Assoian; J M Smith; N S Roche; L M Wakefield; U I Heine; L A Liotta; V Falanga; J H Kehrl
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

4.  Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells.

Authors:  M F Graham; G R Bryson; R F Diegelmann
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

5.  Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways.

Authors:  J Reibman; S Meixler; T C Lee; L I Gold; B N Cronstein; K A Haines; S L Kolasinski; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

6.  Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease.

Authors:  R J Alexander; A Panja; E Kaplan-Liss; L Mayer; R F Raicht
Journal:  Dig Dis Sci       Date:  1995-03       Impact factor: 3.199

7.  Effects of growth factors on an intestinal epithelial cell line: transforming growth factor beta inhibits proliferation and stimulates differentiation.

Authors:  M Kurokowa; K Lynch; D K Podolsky
Journal:  Biochem Biophys Res Commun       Date:  1987-02-13       Impact factor: 3.575

8.  Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis.

Authors:  J L van Laethem; J Deviere; A Resibois; F Rickaert; P Vertongen; H Ohtani; M Cremer; K Miyazono; P Robberecht
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

9.  An index of inflammatory activity in patients with Crohn's disease.

Authors:  P A van Hees; P H van Elteren; H J van Lier; J H van Tongeren
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

10.  In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis.

Authors:  M J Czaja; F R Weiner; K C Flanders; M A Giambrone; R Wind; L Biempica; M A Zern
Journal:  J Cell Biol       Date:  1989-06       Impact factor: 10.539

View more
  22 in total

1.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

2.  Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling.

Authors:  Jurgen J W Mulsow; R William G Watson; John M Fitzpatrick; P Ronan O'Connell
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  Safety and effectiveness of mechanical versus hand suturing of intestinal anastomoses in an animal model of peritonitis.

Authors:  Masaaki Tajima; Yohei Kono; Shigeo Ninomiya; Nwar Tawfik Amin; Masafumi Inomata; Norio Shiraishi; Seigo Kitano
Journal:  Exp Ther Med       Date:  2012-05-23       Impact factor: 2.447

4.  Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis.

Authors:  Yosuke Abe; Mitsuyuki Murano; Naoko Murano; Eijiro Morita; Takuya Inoue; Ken Kawakami; Kumi Ishida; Takanori Kuramoto; Kazuki Kakimoto; Toshihiko Okada; Ken Narabayashi; Eiji Umegaki; Kazuhide Higuchi
Journal:  Dig Dis Sci       Date:  2011-09-11       Impact factor: 3.199

5.  Human macrophage metalloelastase worsens the prognosis of pancreatic cancer.

Authors:  Peter Balaz; Helmut Friess; Yasuo Kondo; Zhaowen Zhu; Arthur Zimmermann; Markus W Büchler
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

6.  Expression of interleukin 8 (IL-8) and substance P in human chronic pancreatitis.

Authors:  P Di Sebastiano; F F di Mola; C Di Febbo; G Baccante; E Porreca; P Innocenti; H Friess; M W Büchler
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

7.  TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis.

Authors:  B Del Zotto; G Mumolo; A M Pronio; C Montesani; R Tersigni; M Boirivant
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

8.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  TGF-beta1 and IGF-1 and anastomotic recurrence of Crohn's disease after ileo-colonic resection.

Authors:  Marco Scarpa; Marina Bortolami; Susan L Morgan; Andromachi Kotsafti; Cesare Ruffolo; Renata D'Incà; Eugenia Bertin; Lino Polese; Davide F D'Amico; Giacomo C Sturniolo; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

10.  Loss of the eukaryotic initiation factor 3f in pancreatic cancer.

Authors:  Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; John T Cunningham; Mark A Nelson; Jiaqi Shi
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.